SURMOUNT-OSA Study 1 recruited patients with OSA who were not on positive airway pressure (PAP) therapy ... in which Lilly is already squaring off with Novo Nordisk and others, with a lengthening ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food ...

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...